Celularity, headquartered in Florham Park, NJ, is a clinical-stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Market Cap | 969.193 Million | Shares Outstanding | 123.464 Million | Avg 30-day Volume | 499.252 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -2.52 |
Price to Revenue | 0.0 | Debt to Equity | 1.7648 | EBITDA | -206.814 Million |
Price to Book Value | 0.0 | Operating Margin | 0.0 | Enterprise Value | 716.221 Million |
Current Ratio | EPS Growth | -25.064 | Quick Ratio | ||
1 Yr BETA | 0.8776 | 52-week High/Low | 13.4 / 3.63 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -5656.1578 | Altman Z-Score | Free Cash Flow to Firm | 61.144 Million | |
Earnings Report | 2022-08-15 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
HARIRI ROBERT J CHIEF EXECUTIVE OFFICER |
|
8,250,724 | 2022-04-13 | 4 |
HAINES JOHN R SEE REMARKS |
|
258,018 | 2022-04-13 | 4 |
GLOVER BRADLEY CHIEF TECHNOLOGY OFFICER |
|
77,407 | 2022-04-13 | 3 |
DUNN KEARY SEE REMARKS |
|
64,505 | 2022-04-13 | 5 |
BEERS DAVID C CHIEF FINANCIAL OFFICER |
|
161,262 | 2022-04-13 | 4 |
JONES ANNE CHIEF BUSINESS OFFICER |
|
64,505 | 2022-04-13 | 3 |
BRIGIDO STEPHEN PRES, FUNCTIONAL REGENERATION |
|
129,010 | 2022-04-13 | 5 |
|
15,281,389 | 2022-03-01 | 3 | |
|
307,437 | 2021-11-09 | 4 | |
PECORA ANDREW L PRESIDENT |
|
2,469,282 | 2021-09-15 | 2 |
MIRAKHUR BELOO EVP, CLINICAL DEVELOPMENT |
|
125,000 | 2021-09-13 | 2 |
|
56,053 | 2021-09-09 | 3 | |
|
56,053 | 2021-09-09 | 2 | |
|
56,053 | 2021-09-09 | 2 | |
|
56,053 | 2021-09-09 | 2 | |
|
56,053 | 2021-09-09 | 3 | |
|
56,053 | 2021-09-09 | 3 | |
|
56,053 | 2021-09-09 | 3 | |
|
20,422,124 | 2021-07-16 | 1 | |
|
8,640,695 | 2021-07-16 | 3 | |
|
100,000 | 2021-07-16 | 1 | |
|
30,062,778 | 2021-07-16 | 1 | |
|
0 | 2019-05-20 | 0 | |
KELLETT ANDREA J. CHIEF FINANCIAL OFFICER |
|
0 | 2019-05-20 | 0 |
MASELLI MICHAEL G VICE PRESIDENT OF ACQUISITIONS |
|
0 | 2019-05-20 | 0 |
|
0 | 2019-05-20 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-04-28 21:04:29 -0400 | 2022-04-13 | A | 16,405 | a | 16,405 | direct | -0.4277 | 4.3627 | 4.3627 | 6 | -2.6518 | 3 | ||||
2022-04-28 21:06:19 -0400 | 2022-04-13 | A | 192,401 | a | 192,401 | direct | ||||||||||
2022-04-28 20:52:54 -0400 | 2022-04-13 | A | 16,405 | a | 16,405 | direct | -0.4277 | 4.3627 | 4.3627 | 6 | -2.6518 | 3 | ||||
GLOVER BRADLEY - Director - Officer CHIEF TECHNOLOGY OFFICER |
2022-04-28 20:55:12 -0400 | 2022-04-13 | A | 57,721 | a | 57,721 | direct | |||||||||
HARIRI ROBERT J - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-04-28 21:05:45 -0400 | 2022-04-13 | A | 131,234 | a | 7,865,923 | direct | -0.4277 | 4.3627 | 4.3627 | 6 | -2.6518 | 3 | |||
2022-04-28 20:59:49 -0400 | 2022-04-13 | A | 96,201 | a | 96,201 | direct | ||||||||||
2022-04-28 21:06:19 -0400 | 2022-04-13 | A | 65,617 | a | 65,617 | direct | -0.4277 | 4.3627 | 4.3627 | 6 | -2.6518 | 3 | ||||
GLOVER BRADLEY - Director - Officer CHIEF TECHNOLOGY OFFICER |
2022-04-28 20:55:12 -0400 | 2022-04-13 | A | 19,686 | a | 19,686 | direct | -0.4277 | 4.3627 | 4.3627 | 6 | -2.6518 | 3 | |||
2022-04-28 20:57:46 -0400 | 2022-04-13 | A | 120,251 | a | 120,251 | direct | ||||||||||
2022-04-28 20:59:49 -0400 | 2022-04-13 | A | 32,809 | a | 32,809 | direct | -0.4277 | 4.3627 | 4.3627 | 6 | -2.6518 | 3 | ||||
2022-04-28 21:04:29 -0400 | 2022-04-13 | A | 48,100 | a | 48,100 | direct | ||||||||||
2022-04-28 20:52:54 -0400 | 2022-04-13 | A | 48,100 | a | 48,100 | direct | ||||||||||
2022-04-28 20:57:46 -0400 | 2022-04-13 | A | 41,011 | a | 41,011 | direct | -0.4277 | 4.3627 | 4.3627 | 6 | -2.6518 | 3 | ||||
HARIRI ROBERT J - Director - Officer CHIEF EXECUTIVE OFFICER |
2022-04-28 21:05:45 -0400 | 2022-04-13 | A | 384,801 | a | 384,801 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
CELULARITY INC CELU | 2022-05-19 18:45:03 UTC | -85.1883 | 86.0083 | 75000 |
CELULARITY INC CELU | 2022-05-19 18:15:03 UTC | -85.1883 | 86.0083 | 75000 |
CELULARITY INC CELU | 2022-05-19 17:45:03 UTC | -85.1883 | 86.0083 | 75000 |
CELULARITY INC CELU | 2022-05-19 17:15:03 UTC | -85.1883 | 86.0083 | 75000 |
CELULARITY INC CELU | 2022-05-19 16:45:03 UTC | -84.6838 | 85.5038 | 75000 |
CELULARITY INC CELU | 2022-05-19 16:15:04 UTC | -84.6838 | 85.5038 | 50000 |
CELULARITY INC CELU | 2022-05-19 15:45:04 UTC | -84.6838 | 85.5038 | 40000 |
CELULARITY INC CELU | 2022-05-19 15:15:03 UTC | -84.6838 | 85.5038 | 40000 |
CELULARITY INC CELU | 2022-05-19 14:45:04 UTC | -87.1364 | 87.9564 | 40000 |
CELULARITY INC CELU | 2022-05-19 14:15:03 UTC | -87.1364 | 87.9564 | 35000 |
CELULARITY INC CELU | 2022-05-19 13:45:03 UTC | -87.1364 | 87.9564 | 40000 |
CELULARITY INC CELU | 2022-05-19 13:15:03 UTC | -87.1364 | 87.9564 | 70000 |
CELULARITY INC CELU | 2022-05-19 12:45:03 UTC | -87.1364 | 87.9564 | 50000 |
CELULARITY INC CELU | 2022-05-18 22:15:03 UTC | -87.1364 | 87.9564 | 40000 |
CELULARITY INC CELU | 2022-05-18 21:45:03 UTC | -87.8783 | 88.6983 | 40000 |
CELULARITY INC CELU | 2022-05-18 21:15:04 UTC | -87.8783 | 88.6983 | 40000 |
CELULARITY INC CELU | 2022-05-18 20:45:03 UTC | -88.5518 | 89.3718 | 35000 |
CELULARITY INC CELU | 2022-05-18 20:15:05 UTC | -88.5518 | 89.3718 | 35000 |
CELULARITY INC CELU | 2022-05-18 19:45:03 UTC | -88.5518 | 89.3718 | 35000 |
CELULARITY INC CELU | 2022-05-18 19:15:03 UTC | -88.5518 | 89.3718 | 35000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|